De PARP-remmer/immunotherapie-paradox bij gevorderd ovariumcarcinoom

Unlocking the immune system with antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen-4 has opened broad new therapeutic areas in oncology, including the treatment of gynaecological cancers involving the endometrium and cervix.1 Not unreasonably, researchers hoped that the benefits of immune checkpoint inhibitors would extend to ovarian cancer, a heterogeneous group of tumours in which previous studies showed that the presence of infiltrating cytotoxic immune cells in the tumour microenvironment indicated immune recognition and as such were associated with better outcomes.